Cowan M J, Shannon K M, Wara D W, Ammann A J
Department of Pediatrics, University of California, San Francisco 94143.
Clin Immunol Immunopathol. 1988 Nov;49(2):242-50. doi: 10.1016/0090-1229(88)90114-6.
Severe combined immunodeficiency disease (SCID) in patients with adenosine deaminase (ADA) deficiency is thought to result from increased levels of purine metabolites. We attempted to immunosuppress a patient with ADA deficiency and SCID using a continuous infusion of deoxyadenosine to obtain engraftment of a T cell-depleted haplocompatible parental bone marrow graft. Before administering the drug in vivo, we investigated hematopoietic colony formation in two children with ADA deficiency (including the potential recipient), the obligate heterozygote donor (father), and normal controls using deoxyadenosine and erythro-9-(2-hydroxy-3-nanyl)adenosine (EHNA), and inhibitor of ADA. Deoxyadenosine alone in concentrations as high as 100 microM had no significant affect on erythroid (BFU-E) or myeloid (CFU-c) colony formation. However, in the presence of EHNA there was a significant reduction in BFU-E and CFU-c growth in all subjects and controls. Increasing doses of deoxyadenosine were given to one patient with ADA deficiency and SCID as a continuous 24-hr intravenous infusion. We found that there was a linear relationship between the dose administered and the plasma level; however, doses greater than 100 mg/day were required to increase erythrocyte dATP levels. We were able to raise intracellular dATP levels to more than three times baseline with doses of deoxyadenosine of 200 mg/day. However, there were no significant effects on the absolute lymphocyte counts or the lymphocyte responses to mitogen or alloantigen, and the haploidentical marrow failed to engraft. Our results suggest that the bone marrow of ADA-deficient patients is normal with respect to standard colony formation, that inhibitors of ADA do not adequately model the deficient state, and that the immunodeficiency in ADA deficiency is not proportionately related to either the deoxyadenosine or dATP levels, both of which were significantly elevated at the time of transplantation.
腺苷脱氨酶(ADA)缺乏症患者的严重联合免疫缺陷病(SCID)被认为是由嘌呤代谢产物水平升高所致。我们尝试通过持续输注脱氧腺苷对一名患有ADA缺乏症和SCID的患者进行免疫抑制,以实现T细胞去除的半相合亲代骨髓移植的植入。在体内给药之前,我们使用脱氧腺苷和红细胞-9-(2-羟基-3-壬基)腺苷(EHNA,一种ADA抑制剂),对两名ADA缺乏症儿童(包括潜在接受者)、必然杂合子供体(父亲)和正常对照进行了造血集落形成研究。单独使用浓度高达100微摩尔的脱氧腺苷对红系(BFU-E)或髓系(CFU-c)集落形成没有显著影响。然而,在存在EHNA的情况下,所有受试者和对照组的BFU-E和CFU-c生长均显著降低。对一名患有ADA缺乏症和SCID的患者进行持续24小时静脉输注递增剂量的脱氧腺苷。我们发现给药剂量与血浆水平之间存在线性关系;然而,需要大于100毫克/天的剂量才能提高红细胞dATP水平。使用200毫克/天的脱氧腺苷剂量,我们能够将细胞内dATP水平提高到基线水平的三倍以上。然而,对绝对淋巴细胞计数或淋巴细胞对有丝分裂原或同种异体抗原的反应没有显著影响,半相合骨髓未能植入。我们的结果表明,ADA缺乏症患者的骨髓在标准集落形成方面是正常的,ADA抑制剂不能充分模拟缺陷状态,并且ADA缺乏症中的免疫缺陷与脱氧腺苷或dATP水平均不成比例相关,在移植时这两者均显著升高。